前列腺癌诊断市场－全球产业规模、份额、趋势、机会和预测，按检测类型、类型、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球前列腺癌诊断市场规模为89.2亿美元，预计到2030年将以9.25%的复合年增长率增长至151.7亿美元。前列腺癌诊断涵盖一系列用于检测、表征和分期前列腺癌的医疗程序和检测方法，包括前列腺特异性抗原（PSA）血液检测、直肠指检、各种影像学检查和活检。推动市场成长的主要因素包括全球人口老化、前列腺癌发病率和盛行率的上升、公众意识的提高以及筛检力度的加强，以及诊断方法技术的不断进步。

主要市场驱动因素

全球前列腺癌发病率的不断上升显着推动了诊断市场的发展，因为医疗保健系统正面临日益沉重的疾病负担。这种不断上升的盛行率要求我们采用更频繁、更先进的筛检方法、早期检测手段以及持续监测策略。

主要市场挑战

全球前列腺癌诊断市场扩张的一大障碍是先进诊断技术的高成本。这些高昂的成本给医疗系统和患者个人带来了沉重的经济负担，尤其是在医疗基础设施欠发达的地区，预算往往有限，报销机制可能不足以支付专业诊疗费用。

主要市场趋势

全球前列腺癌诊断市场受到诊断服务向门诊和家庭环境分散化的显着影响。这一趋势代表着医疗服务模式的根本性转变，即从传统的以医院为中心的模式转向更便捷、更易于获取的诊断方案。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球前列腺癌诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依测试类型（初步测试、确认测试）
  • 按类型（腺癌、间质细胞癌、其他）
  • 依最终用途（医院和诊所、门诊中心、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美前列腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲摄护腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区摄护腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲前列腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲摄护腺癌诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球前列腺癌诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• MDx Health, Inc.
• Myriad Genetics, Inc.
• Abbott Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Siemens Healthcare AG
• OPKO Health, Inc.
• Exact Sciences Corporation
• Regeneron Pharmaceuticals Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Prostate Cancer Diagnostics Market, valued at USD 8.92 Billion in 2024, is projected to experience a CAGR of 9.25% to reach USD 15.17 Billion by 2030. Prostate cancer diagnostics encompass a suite of medical procedures and tests employed for the detection, characterization, and staging of prostate cancer, including prostate-specific antigen blood tests, digital rectal examinations, various imaging modalities, and biopsy procedures. The market's expansion is primarily propelled by an aging global demographic, the increasing incidence and prevalence of prostate cancer, growing public awareness coupled with enhanced screening initiatives, and continuous technological advancements in diagnostic methodologies.

Key Market Drivers

The increasing global incidence of prostate cancer significantly propels the diagnostics market, as healthcare systems contend with a growing disease burden. This rising prevalence necessitates more frequent and advanced screening, early detection methods, and ongoing monitoring strategies. According to the American Cancer Society, in its January 2024 "Cancer Statistics, 2024" report, nearly 300,000 new cases of prostate cancer were expected in the United States during the year, highlighting the persistent diagnostic demand.

Key Market Challenges

A significant impediment to the expansion of the Global Prostate Cancer Diagnostics Market is the considerable cost associated with advanced diagnostic technologies. These high costs place a substantial financial burden on healthcare systems and individual patients, particularly in regions with developing healthcare infrastructures where budgets are often constrained and reimbursement mechanisms may be insufficient for specialized procedures. This economic barrier directly impacts the ability of healthcare providers to procure and deploy necessary diagnostic equipment and expertise, thus limiting the availability of comprehensive diagnostic services.

Key Market Trends

The Global Prostate Cancer Diagnostics Market is significantly influenced by the decentralization of diagnostic services to outpatient and home settings. This trend represents a fundamental shift in healthcare delivery, moving away from traditional hospital-centric models towards more accessible and convenient diagnostic options. The adoption of at-home collection methods for prostate cancer screening is gaining traction, driven by advancements in non-invasive testing. For instance, in February 2025, Lynx Dx announced the commercial launch of MyProstateScore 2.0 for at-home collection by patients, a test designed to accurately predict the risk of clinically significant prostate cancer using urine samples collected without a digital rectal exam.

Key Market Players

• MDx Health, Inc.
• Myriad Genetics, Inc.
• Abbott Laboratories, Inc.
• F. Hoffman-La Roche Ltd.
• Siemens Healthcare AG
• OPKO Health, Inc.
• Exact Sciences Corporation
• Regeneron Pharmaceuticals Inc.

Report Scope:

In this report, the Global Prostate Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Prostate Cancer Diagnostics Market, By Test Type:

• Preliminary Tests
• Confirmatory Tests

Prostate Cancer Diagnostics Market, By Type:

• Adenocarcinoma
• Interstitial cell carcinoma
• Others

Prostate Cancer Diagnostics Market, By End use:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Prostate Cancer Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Prostate Cancer Diagnostics Market.

Available Customizations:

Global Prostate Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Prostate Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Preliminary Tests, Confirmatory Tests)
  • 5.2.2. By Type (Adenocarcinoma, Interstitial cell carcinoma, Others)
  • 5.2.3. By End use (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Prostate Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By Type
  • 6.2.3. By End use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Prostate Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By End use
  • 6.3.2. Canada Prostate Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By End use
  • 6.3.3. Mexico Prostate Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By End use

7. Europe Prostate Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By Type
  • 7.2.3. By End use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Prostate Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By End use
  • 7.3.2. France Prostate Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By End use
  • 7.3.3. United Kingdom Prostate Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By End use
  • 7.3.4. Italy Prostate Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By End use
  • 7.3.5. Spain Prostate Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By End use

8. Asia Pacific Prostate Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By Type
  • 8.2.3. By End use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Prostate Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By End use
  • 8.3.2. India Prostate Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By End use
  • 8.3.3. Japan Prostate Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By End use
  • 8.3.4. South Korea Prostate Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By End use
  • 8.3.5. Australia Prostate Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By End use

9. Middle East & Africa Prostate Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By Type
  • 9.2.3. By End use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Prostate Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By End use
  • 9.3.2. UAE Prostate Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By End use
  • 9.3.3. South Africa Prostate Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By End use

10. South America Prostate Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By Type
  • 10.2.3. By End use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Prostate Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By End use
  • 10.3.2. Colombia Prostate Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By End use
  • 10.3.3. Argentina Prostate Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By End use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Prostate Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. MDx Health, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Myriad Genetics, Inc.
• 15.3. Abbott Laboratories, Inc.
• 15.4. F. Hoffman-La Roche Ltd.
• 15.5. Siemens Healthcare AG
• 15.6. OPKO Health, Inc.
• 15.7. Exact Sciences Corporation
• 15.8. Regeneron Pharmaceuticals Inc.

16. Strategic Recommendations

17. About Us & Disclaimer